Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIMABOTULINUMTOXINB vs RISDIPLAM: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIMABOTULINUMTOXINB vs RISDIPLAM: Safety Overview

Metric RIMABOTULINUMTOXINB RISDIPLAM
Total FAERS Reports 176 3,619
Deaths Reported 38 336
Death Rate 21.6% 9.3%
Hospitalizations 35 719
Average Patient Age 59.0 yrs 21.8 yrs
% Female Patients 68.6% 55.2%
FDA Approval Date N/A Aug 7, 2020
Manufacturer Solstice Neurosciences, LLC Genentech, Inc.
Route INTRAMUSCULAR ORAL
Marketing Status N/A Prescription